Trevi Therapeutics, Inc.
HealthcareNASDAQ:TRVI · NASDAQ Global Market
+$0.75 today
Vol 1.51M · Avg 1.43M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-23.3%
avg -64.2%
ROIC
-26.8%
avg -68.8%
ROA
-22.1%
avg -61.3%
Analysis
ROA is currently the strongest return metric at -22.1% versus its period average of -61.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jennifer L. Good | Co-Founder, Chief Executive Officer, President & Director | $976,632.00 | — | 61 | $675,000.00 | 0.48% |
James V. Cassella | Chief Development Officer | $694,770.00 | — | 71 | $215,000.00 | 0.15% |
Thomas R. Sciascia | Co-Founder & Chief Scientific Officer | $551,426.00 | — | 73 | $35,000.00 | 0.02% |
Farrell Simon | Chief Commercial Officer | $530,567.00 | — | — | $160,000.00 | 0.11% |
David C. Hastings | Chief Financial Officer & Principal Financial Officer | — | — | 65 | $35,000.00 | 0.02% |
Katherine Takaki | Senior Vice President of Global Regulatory Affairs | — | — | — | — | — |
Katie McManus | Communications Manager | — | — | — | — | — |
Christopher Galletta | Controller & Chief Accounting Officer | — | — | 48 | $35,000.00 | 0.02% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Terns Pharmaceuticals, Inc.
TERN
$4.77B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
Novavax, Inc.
NASDAQ:NVAX
$1.46B
Ardelyx, Inc.
NASDAQ:ARDX
$1.41B
Precigen, Inc.
NASDAQ:PGEN
$1.34B
Tourmaline Bio, Inc.
TRML
$1.23B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.13B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$883.93M
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Upstream Bio, Inc.
UPB
$331.96M
Who manages TRVI?
Trevi Therapeutics, Inc. (TRVI) lists 8 active executives. The top listed executive is Jennifer L. Good, Co-Founder, Chief Executive Officer, President & Director.
Are TRVI insiders buying or selling?
Recent insider activity shows net buying of $12.32M.
Explore More
Continue the stock analysis
Jump to another research area for this company.